CALDERWOOD & HARKNESS LLP
CONFIDENTIAL — ATTORNEY WORK PRODUCT
MEMORANDUM
TO: Capital Markets Practice Group; File
FROM: Theodore Langston, Responsible Partner, Capital Markets
DATE: March 8, 2024
RE: Post-Closing Memorandum and Lessons Learned — Initial Public Offering of Common Stock of Arbor Health Technologies Inc. (NYSE: ARHT)
MATTER NUMBER: 1010-00002
CC: Vivienne St. Claire (Billing Partner); Eric Johannsen (Lead Associate); Claire Dempsey (Working Associate); Sylvia Hartwell (Specialist Partner, Tax)
This memorandum constitutes privileged attorney work product and is protected by the attorney-client privilege. It is intended solely for internal use by Calderwood & Harkness LLP attorneys and professional staff. This memorandum should not be disclosed to any third party without the prior written approval of the Responsible Partner.
Right-click to update Table of Contents
I. Executive Summary
This memorandum is an internal post-mortem analysis summarizing the completed initial public offering of common stock of Arbor Health Technologies Inc. ("AHT" or the "Company"). It is prepared for the firm's institutional knowledge base and is intended to serve as a reference resource for future engagements involving healthcare SaaS and healthcare services company initial public offerings. The memorandum addresses the full lifecycle of the engagement — from retention through closing and overallotment settlement — and distills key lessons learned across the SEC comment process, pricing dynamics, lock-up negotiations, underwriting agreement terms, corporate governance structuring, equity compensation planning, credit facility coordination, tax analysis, and working group management.
Client. The client is Arbor Health Technologies Inc., a corporation organized under the laws of the State of Delaware, headquartered at 275 Kendall Avenue, Suite 1400, Cambridge, Massachusetts 02142. AHT is a healthcare services and software-as-a-service ("SaaS") company operating a cloud-based clinical decision support and population health management platform, supplemented by revenue cycle management outsourcing and real-time analytics services.
Transaction. The transaction comprised an initial public offering of 20,000,000 shares of common stock, par value $0.001 per share, on the New York Stock Exchange under the ticker symbol "ARHT" (CUSIP 039217105; SEC File Number 333-276841; CIK 0001987432). The final IPO price was $20.00 per share, which priced above the original estimated range of $17.00–$19.00 per share. Following strong roadshow demand, the range was subsequently raised to $18.00–$20.00 per share, and the offering priced at the top of the revised range. The base offering generated gross proceeds of $400,000,000. The underwriters exercised the overallotment option in full for an additional 3,000,000 shares, bringing total gross proceeds to $460,000,000.
Post-IPO Market Capitalization. At the IPO price of $20.00 per share, the Company's post-IPO market capitalization was approximately $2,060,000,000, based on 103,000,000 shares of common stock outstanding (comprising 80,000,000 pre-IPO shares, 20,000,000 base offering shares, and 3,000,000 overallotment shares).
Timeline. The engagement was opened on August 21, 2023, and the base offering closed on February 13, 2024. The overallotment shares settled on March 1, 2024. The matter is currently designated as closed_completed. Total elapsed time from engagement opening to base closing was approximately five months and twenty-three days.
Calderwood & Harkness Engagement Team. The C&H team consisted of Theodore Langston (Responsible Partner, Capital Markets), Vivienne St. Claire (Billing Partner), Eric Johannsen (Lead Associate), Claire Dempsey (Working Associate), and Sylvia Hartwell (Specialist Partner, Tax).
II. Transaction Overview
A. Parties and Roles
Issuer. Arbor Health Technologies Inc. is a Delaware C-corporation (EIN 47-3891205) founded in 2014 by Dr. Nathaniel Rourke and Margaret Tsujimoto. The Company operates a cloud-based clinical decision support and population health management platform serving over 1,200 hospital systems and physician groups across 42 states. In addition to its core SaaS platform, AHT provides revenue cycle management outsourcing services and real-time healthcare analytics solutions. As of December 31, 2023, the Company employed approximately 3,400 individuals.
Key AHT Executives. The following individuals served as the principal executive officers and key management of the Company throughout the engagement:
• Dr. Nathaniel Rourke — Co-Founder, Chairman of the Board, and Chief Executive Officer. Dr. Rourke held 12,800,000 pre-IPO shares, representing 16.0% of pre-IPO outstanding common stock.
• Margaret "Meg" Tsujimoto — Co-Founder and Chief Technology Officer. Ms. Tsujimoto held 9,600,000 pre-IPO shares, representing 12.0% of pre-IPO outstanding common stock.
• David Halderman — Chief Financial Officer. Mr. Halderman held 2,400,000 pre-IPO shares, representing 3.0% of pre-IPO outstanding common stock.
• Rachel Moynihan — General Counsel and Corporate Secretary. Ms. Moynihan held 1,200,000 pre-IPO shares, representing 1.5% of pre-IPO outstanding common stock. Ms. Moynihan served as the primary client contact throughout the engagement.
• Dr. Priya Subramanian — Chief Medical Officer. Dr. Subramanian held 1,600,000 pre-IPO shares, representing 2.0% of pre-IPO outstanding common stock.
Pre-IPO Institutional Investors (Not Selling in the IPO). No existing stockholders sold shares in the offering. The following institutional investors held significant pre-IPO positions:
• Brindoval Trelvon Partners Fund IV, L.P. — 28,000,000 shares (35.0% pre-IPO; approximately 27.18% post-IPO). Brindoval Summit's board designees were Leonard Corbett and Diana Coltrane, each of whom served as directors of the Company throughout the engagement and continue to serve in that capacity post-IPO.
• Ridgeline Growth Equity Fund III, LLC — 16,000,000 shares (20.0% pre-IPO; approximately 15.53% post-IPO). Ridgeline's board designee was Howard Feng, who served as a director throughout the engagement and continues to serve post-IPO.
Independent Directors. The Board of Directors included two independent directors not affiliated with any pre-IPO investor: Carolyn Whittemore and Dr. Samuel Obadina. Both were appointed in anticipation of the IPO to satisfy NYSE independence requirements.
Underwriters. The underwriting syndicate comprised the following:
• Lead Left Bookrunner: Whitfield Barrow & Co., LLC (contacts: Jonathan Pritchett, Managing Director, and Sarah Langley-Kwan, Executive Director). Whitfield Barrow managed 10,000,000 shares (50.0% of the base offering) and served as the Representative of the several underwriters.
• Joint Bookrunners: Calloway Pierce Securities LLC (contacts: Marcus Delgado, Managing Director, and Anita Pham, Vice President) — 6,000,000 shares (30.0% of the base offering); Velthorn Capital Partners Inc. (contact: Robert Acheson, Managing Director) — 2,400,000 shares (12.0% of the base offering).
• Co-Manager: Pemberton Wallis LLC (contact: Elena Vasquez, Director) — 1,600,000 shares (8.0% of the base offering).
Underwriters' Counsel. Meridian Hale & Quivorn LLP served as counsel to the underwriters. The principal contacts were Graham Neville (Partner) and Kathryn Brennan (Senior Associate).
Auditors. Kellerman & Associates LLP served as the Company's independent registered public accounting firm. The engagement partner was Richard Olander, with Sonia Melendez serving as the senior manager on the engagement team. Kellerman audited the Company's financial statements for fiscal years 2021, 2022, and 2023, all of which were included in the Registration Statement.
Transfer Agent and Registrar. Continental Share Services, Inc. served as the transfer agent and registrar for the Company's common stock.
Financial Printer and EDGAR Agent. Toppan Quillon Health IT provided financial printing and EDGAR filing services throughout the offering process.
Compensation Consultant. Hargrove Prindaux Advisory Group LLC served as the Company's independent compensation consultant in connection with the IPO and the design of the 2024 equity compensation plans. The compensation consultant's independence was disclosed in the Registration Statement.
Operating Bank and Credit Facility Agent. Keypoint National Bank, N.A. served as the administrative agent under the Company's senior secured revolving credit facility. Stonemill Capital Bank served as a syndicate member under the credit facility.
Directors and Officers Insurance. The Company procured a three-layer D&O insurance tower with a total limit of $100,000,000, effective upon the IPO. The program was structured as follows:
• Primary Layer: Northbridge Specialty Insurance Company — $50,000,000 per occurrence/aggregate.
• 1st Excess Layer: Pinnacle Re Assurance Ltd. — $25,000,000 in excess of $50,000,000.
• 2nd Excess Layer: Atlas Guard Insurance Company — $25,000,000 in excess of $75,000,000.
B. Offering Structure and Economics
The offering was structured as an entirely primary offering. No existing stockholders sold shares. This all-primary structure reflected the Company's desire to maximize proceeds available for corporate purposes, the institutional investors' preference to maintain their ownership positions through the lock-up period, and the underwriters' view that an all-primary deal would be received favorably by institutional investors as a sign of insider confidence.
Base Offering. The base offering consisted of 20,000,000 shares of common stock at a public offering price of $20.00 per share, generating gross proceeds of $400,000,000.
Overallotment Option. The underwriters were granted an option to purchase up to 3,000,000 additional shares of common stock (15% of the base offering) at the public offering price, less the underwriting discount. The overallotment option was exercised in full on February 27, 2024, generating additional gross proceeds of $60,000,000. Total gross proceeds, inclusive of the overallotment, were $460,000,000.
Underwriting discount. The underwriting discount was 6.0% of the public offering price, or $1.20 per share. The total underwriting discount was $27,600,000 (calculated on 23,000,000 total shares sold). The discount was allocated among the syndicate as follows:
• Management fee: 20% ($5,520,000)
• Selling concession: 60% ($16,560,000)
• Underwriting fee: 20% ($5,520,000)
Net Proceeds to the Company. Net proceeds to the Company from the base offering (after deducting the underwriting discount) were $376,000,000. Net proceeds from the total offering (including the overallotment) were $432,400,000.
Estimated Offering Expenses (Excluding Underwriting discount). Total estimated offering expenses, exclusive of the underwriting discount, were approximately $4,200,000, broken down as follows:
Net Proceeds After All Expenses. After deducting both the underwriting discount and estimated offering expenses, net proceeds to the Company from the total offering (including the overallotment) were approximately $428,200,000.
C. Post-IPO Capitalization Summary
The following table sets forth the Company's capitalization immediately following the closing of the offering, including the exercise in full of the overallotment option:
Post-IPO Ownership Table.
Market Capitalization and Implied Valuation. At the IPO price of $20.00 per share, the Company's post-IPO market capitalization was $2,060,000,000 (103,000,000 shares × $20.00). This implied a valuation multiple of approximately 3.36x the Company's FY2023 revenue of $612.4 million and approximately 14.85x the Company's FY2023 Adjusted EBITDA of $138.7 million.
D. Use of Proceeds
As disclosed in the final prospectus, the Company intended to use the net proceeds from the offering for the following purposes:
1. Repayment of Indebtedness. Approximately $65,000,000 to repay the outstanding balance on the Keypoint National Bank revolving credit facility, which bore interest at SOFR plus 200 basis points. The credit facility will remain in place following such repayment, providing the Company with continued access to the revolving commitment for working capital and other general corporate purposes.
2. Product Development and R&D Investment. Approximately $120,000,000 to fund investment in product development and research and development, including enhancement of the Company's clinical decision support platform, expansion of its population health management capabilities, and development of new real-time analytics modules.
3. Potential Acquisitions and Strategic Investments. Approximately $100,000,000 to fund potential acquisitions of, or strategic investments in, complementary businesses, technologies, and product offerings. While the Company did not have any specific acquisitions or investments identified at the time of the offering, management has indicated that the Company continually evaluates opportunities in the healthcare services and technology landscape.
4. General Corporate Purposes and Working Capital. The balance of net proceeds was designated for general corporate purposes and working capital needs, providing the Company with financial flexibility as it scales its operations.
III. Timeline and Key Milestones
The following chronological summary reflects the key milestones of the engagement from inception through final closing of the overallotment:
Elapsed Time Summary. Total elapsed time from engagement opening (August 21, 2023) to base closing (February 13, 2024) was approximately five months and twenty-three days. The period from confidential submission (November 10, 2023) to effectiveness (February 8, 2024) was approximately 90 days, which is within the typical range for a healthcare SaaS issuer with a two-round SEC comment process.
IV. SEC Comment Letter Process and Themes
A. Overview
The Registration Statement was subject to two rounds of review and comment by the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Round 1 consisted of 38 comments received on December 8, 2023, to which the working group submitted a comprehensive response and amended draft S-1 on December 22, 2023, achieving a 14-day turnaround. Round 2 consisted of 11 follow-up comments received on January 12, 2024, to which the working group responded on January 19, 2024, achieving a 7-day turnaround. No third round of comments was received, and the Registration Statement was cleared for public filing on January 22, 2024.
All response letters were prepared by C&H (Theodore Langston and Eric Johannsen, with working-level drafting contributions from Claire Dempsey) with significant substantive input from AHT management — particularly David Halderman (CFO) and Rachel Moynihan (General Counsel) — and from Kellerman & Associates (Richard Olander and Sonia Melendez) on accounting-related comments. The response strategy emphasized direct, responsive answers to each Staff comment, supplemented by specific references to revised disclosure in the amended Registration Statement where applicable.
B. Round 1 Comment Themes (38 Comments)
The 38 Round 1 comments covered a range of topics, which are organized below by thematic area. The comment totals by theme are approximations, as certain comments touched on multiple topics.
Revenue Recognition (Approximately 8–10 Comments). The Staff devoted substantial attention to the Company's application of ASC 606 (Revenue from Contracts with Customers) to AHT's hybrid business model, which encompasses both SaaS subscription revenue (the core clinical decision support and population health management platform) and revenue cycle management outsourcing fees (which are priced on a percentage-of-collections or per-transaction basis). Specific areas of inquiry included: (i) the allocation of transaction price across bundled arrangements where customers purchase both the SaaS platform and outsourced revenue cycle management services; (ii) the timing of revenue recognition for multi-element arrangements, including the identification of distinct performance obligations; (iii) the disclosure of significant judgments and estimates involved in applying the five-step revenue recognition model; and (iv) a request for additional quantitative breakdown of recurring subscription revenue versus non-recurring or transaction-based revenue streams to enable investors to evaluate the quality and predictability of AHT's revenue base. The response included enhanced narrative disclosure in the "Critical Accounting Policies and Estimates" section of MD&A, additional tabular disclosure disaggregating revenue by type and by geography, and supplemental explanatory language regarding the Company's approach to identifying performance obligations in bundled contracts.
Non-GAAP Financial Measures (Approximately 5–6 Comments). The Staff raised several comments concerning the Company's presentation and reconciliation of Adjusted EBITDA, which was a key financial metric highlighted in the prospectus. Specific concerns included: (i) the appropriateness of certain adjustments, particularly the add-back of stock-based compensation expense, certain one-time integration costs associated with a 2022 tuck-in acquisition, and reserves associated with pending litigation; (ii) the prominence of GAAP measures relative to non-GAAP measures (the Staff requested that the GAAP reconciliation be placed in closer proximity to the Adjusted EBITDA discussion); and (iii) a request for additional narrative explaining why management believed Adjusted EBITDA provided meaningful supplemental information to investors. The FY2023 Adjusted EBITDA margin was 22.6% ($138.7 million on revenue of $612.4 million). The response included revised presentation placing the GAAP-to-non-GAAP reconciliation table immediately adjacent to the Adjusted EBITDA discussion, enhanced prominence of GAAP net income throughout the prospectus, and additional explanatory language addressing each adjustment.
Risk Factor Specificity (Approximately 6–8 Comments). The Staff requested that the Company tailor several risk factors that were deemed overly generic to AHT's specific business circumstances. This included: (i) cybersecurity risk factors, which the Staff requested be revised to address the specific types of patient health information and protected health information processed by the AHT platform; (ii) regulatory risk factors, which required expansion to address HIPAA/HITECH compliance, the Stark Law, the Anti-Kickback Statute, and state-level healthcare regulations applicable to AHT's business; (iii) competitive landscape risk factors, which the Staff asked to quantify with specific reference to AHT's competitive positioning relative to identified competitors; and (iv) the reordering of risk factors to present the most material and company-specific risks first. The response included a comprehensive restructuring of the risk factors section, moving the most company-specific risks to the beginning and adding substantial quantitative detail throughout.
Related Party Transactions (Approximately 4–5 Comments). The Staff requested enhanced disclosure regarding the Company's transactions with Brindoval Trelvon Partners and Ridgeline Growth Equity, including management fees, expense reimbursements, and any other financial arrangements. The Staff also inquired about the composition of the Board of Directors and the influence of pre-IPO investors on corporate governance decisions. Specific disclosure was requested regarding the Amended and Restated Investors' Rights Agreement dated October 22, 2020, including the circumstances of its adoption, the rights conferred on the investor parties, and the anticipated termination upon a Qualified IPO. The Registration Rights Agreement was also the subject of enhanced disclosure.
Executive Compensation (Approximately 4–5 Comments). The Staff requested additional disclosure regarding pre-IPO equity grants under the 2014 Stock Incentive Plan, including the methodology for determining the fair value of common stock prior to the IPO. The Staff specifically inquired about the Company's use of Section 409A valuations, the timing and results of the most recent 409A valuation, and the involvement and independence of the Hargrove Prindaux Advisory Group LLC as the Company's compensation consultant. The Staff also requested enhanced detail regarding the terms of the 2024 Equity Incentive Plan and the 2024 Employee Stock Purchase Plan, including share reserves, vesting schedules, and administration provisions. The "cheap stock" issue — the significant differential between the weighted average exercise price of outstanding options ($3.25) and the anticipated IPO price — was flagged as an area requiring further discussion.
Other Comments. The remaining comments addressed range topics, including: (i) MD&A discussion of seasonality and trends affecting the Company's business, with the Staff requesting quantification of any seasonal patterns in revenue and customer acquisition; (ii) the business section's discussion of the competitive landscape, with the Staff requesting specific identification of principal competitors and quantified market share data where available; (iii) legal proceedings disclosure, with the Staff requesting additional detail regarding certain pending litigation matters; (iv) use of proceeds specificity, with the Staff requesting more granular disclosure of the anticipated allocation of proceeds; and (v) the dilution table methodology, with the Staff requesting clarification of certain calculations.
C. Round 2 Comment Themes (11 Comments)
The 11 Round 2 comments were narrower in scope and reflected follow-up on themes initially raised in Round 1.
Segment Reporting (Approximately 3–4 Comments). The Staff requested additional information regarding whether the Company should report operating segments separately under ASC 280 (Segment Reporting), given its two distinct business lines: (i) the clinical decision support and population health management SaaS platform, and (ii) the revenue cycle management outsourcing business. The Staff specifically inquired about the Company's chief operating decision maker ("CODM") analysis, including the nature of the financial information regularly reviewed by the CODM, the organizational structure of the Company, and the basis on which resource allocation decisions are made. The response included a detailed CODM analysis demonstrating that the CEO reviewed consolidated financial information and that the two business lines were managed as a single operating segment with shared infrastructure, technology platform, and go-to-market resources. The Staff accepted this analysis without further comment.
Stock-Based Compensation Expense Assumptions (Approximately 3–4 Comments). The Staff followed up on the "cheap stock" issue raised in Round 1, requesting additional detail regarding the fair value estimation methodology for outstanding options under the 2014 Stock Incentive Plan. Specific inquiries addressed: (i) the weighted average exercise price of outstanding options ($3.25 per share) relative to the anticipated IPO price; (ii) the volatility assumptions used in the Black-Drubeck model; (iii) the expected term calculations; and (iv) a request for a tabular comparison of the most recent Section 409A valuation to the IPO price, with an explanation of any significant difference. This "cheap stock" analysis is discussed further in Section X below.
Cybersecurity Risk Disclosures (Approximately 3–4 Comments). The Staff requested further enhancement of cybersecurity-related disclosures in light of the SEC's new cybersecurity disclosure rules adopted in July 2023 (effective December 2023 for accelerated filers and June 2024 for smaller reporting companies). Specific requests included: (i) additional detail regarding the Board's oversight of cybersecurity risks, including the frequency and nature of Board-level cybersecurity briefings; (ii) disclosure of the Company's incident response procedures and the role of the Chief Information Security Officer; and (iii) enhanced risk factor disclosure addressing the nature and volume of patient health data processed by the AHT platform, including protected health information under HIPAA. The response included a new sub-section in the prospectus under "Business — Cybersecurity" and enhanced risk factor language.
D. Key Observations for Future Engagements
The SEC comment process for AHT yielded several observations that should inform future healthcare SaaS IPO engagements:
1. Non-GAAP Measures. The SEC Staff is increasingly focused on non-GAAP financial measures for SaaS and healthcare services companies. For future engagements, the firm should prepare detailed reconciliation tables and conduct a prominence analysis early in the S-1 drafting process to avoid time-consuming revisions during the comment period.
2. "Cheap Stock" Analysis. The "cheap stock" analysis for pre-IPO equity grants continues to be a significant area of Staff scrutiny, particularly where there is a wide spread between the exercise price and the anticipated IPO price. The firm should recommend that issuers engage a Section 409A valuation firm early in the IPO process and maintain contemporaneous documentation of all valuation methodologies, assumptions, and conclusions. The AHT experience — where the weighted average exercise price was $3.25 compared to the $20.00 IPO price — illustrates the degree of Staff interest in this area.
3. Cybersecurity Disclosures. The new SEC cybersecurity disclosure rules require early attention for healthcare companies that process protected health information. The firm should build governance and risk factor disclosures addressing cybersecurity from the first draft of the Registration Statement to minimize comment exposure.
4. Comment Process Efficiency. The two-round comment process with a total of 49 comments was within the normal range for healthcare SaaS IPOs. The 14-day turnaround on Round 1 and the 7-day turnaround on Round 2 were critical to achieving the target public filing date of January 22, 2024, and maintaining the roadshow and pricing timeline. Rapid turnaround requires pre-positioned working group resources and daily coordination calls during the comment response period.
V. Pricing Dynamics and Range Revision
A. Original Price Range and Market Context
The initial Registration Statement filed publicly on January 22, 2024, included an estimated price range of $17.00 to $19.00 per share, with a midpoint of $18.00 per share. This range was established through a collaborative process involving the Company's management team, the lead left bookrunner (Whitfield Barrow), and the joint bookrunners, and was based on: (i) comparable company analysis, examining publicly traded healthcare SaaS and healthcare services companies with similar revenue profiles, growth rates, and margin characteristics; (ii) discounted cash flow analysis incorporating management's internal financial projections; and (iii) preliminary indications of interest from institutional investors gathered during confidential testing-the-waters meetings conducted prior to the public filing.
The Company's financial profile was supportive of the initial range. AHT reported FY2023 revenue of $612.4 million, representing 28% year-over-year growth from $478.4 million in FY2022. FY2023 Adjusted EBITDA was $138.7 million (22.6% margin), and net income was $41.3 million. The Company is classified under SIC Code 7372 (Prepackaged Software). At the midpoint of the initial range ($18.00), the implied post-IPO market capitalization would have been approximately $1,854,000,000, or approximately 3.03x FY2023 revenue and 13.37x FY2023 Adjusted EBITDA.
B. Roadshow and Demand Build
The roadshow commenced on January 29, 2024, and concluded on February 7, 2024, spanning 10 business days. The management team — led by Dr. Nathaniel Rourke (CEO), David Halderman (CFO), and Dr. Priya Subramanian (CMO) — conducted presentations in New York, Boston, San Francisco, Chicago, and London, with supplemental one-on-one and small group meetings with institutional investors.
Demand was strong across both healthcare-focused and generalist growth equity institutional accounts. The order book was meaningfully oversubscribed, with high-quality anchor orders from long-only healthcare and technology funds. Whitfield Barrow reported to C&H and AHT management that the quality of the order book — characterized by strong participation from long-duration institutional investors rather than short-term or speculative accounts — supported a range increase. Jonathan Pritchett and Sarah Langley-Kwan of Whitfield Barrow specifically recommended the range increase based on their assessment of pricing tension within the book and the competitive dynamics among investors seeking meaningful allocations.
C. Range Raise
On February 3, 2024, C&H held a discussion with AHT management — specifically Rachel Moynihan and David Halderman — regarding the proposed range increase. C&H outlined the mechanics and requirements for filing an amendment to the Registration Statement (Form S-1/A), including the need to update the capitalization table, dilution analysis, and pro forma financial data to reflect the revised price range. C&H also discussed the practical timing considerations, including the need to file the amendment sufficiently in advance of the expected effectiveness date to allow the SEC Staff adequate time for review.
Amendment No. 1 to Form S-1/A was filed with the SEC on February 5, 2024. The revised price range was set at $18.00 to $20.00 per share, representing a $1.00 increase to both the low end and the high end of the range. The amendment included updated capitalization and dilution tables reflecting the revised range, updated use of proceeds calculations, and conforming changes throughout the prospectus.
D. Final Pricing
The IPO was priced at $20.00 per share on February 8, 2024 — the top of the revised range of $18.00 to $20.00 and above the midpoint of the original range of $17.00 to $19.00. The deal is properly characterized as "priced above range" because the initial range was $17.00–$19.00, and the $20.00 pricing exceeded the high end of that original range.
On February 8, 2024, the Pricing Committee of the Board of Directors adopted resolutions authorizing: (i) the final public offering price of $20.00 per share; (ii) the underwriting discount of $1.20 per share (6.0%); (iii) the execution and delivery of the Underwriting Agreement; and (iv) the issuance of up to 23,000,000 shares of common stock (including 20,000,000 base offering shares and 3,000,000 overallotment shares).
Lessons Learned. For high-quality healthcare SaaS issuers with strong growth metrics, setting a conservative initial price range with room for a subsequent upward revision can generate positive momentum and favorable pricing tension. The AHT experience demonstrates that a range raise following a strong roadshow creates a positive narrative among investors and financial media, reinforcing demand and supporting pricing at the top of the range. This "build momentum" strategy worked particularly well for AHT, and the firm should recommend discussing this approach with lead bookrunners early in the engagement for issuers with similar profiles. It is critical, however, to have the Amendment No. 1 mechanics — including the updated S-1/A filing, revised capitalization and dilution analysis, and conforming changes — teed up and substantially prepared in advance of a potential range raise so that the amendment can be filed promptly without delaying the roadshow or effectiveness timeline.
VI. Underwriting Agreement Negotiation
A. Process
The Underwriting Agreement was negotiated between C&H (on behalf of the Company) and Meridian Hale & Quivorn LLP (on behalf of the underwriters, with Whitfield Barrow & Co., LLC acting as the Representative of the several underwriters). The negotiation process proceeded as follows:
Whitfield Barrow circulated the initial draft Underwriting Agreement through Meridian Hale on approximately January 15, 2024. The draft was based on Whitfield Barrow's standard form for equity capital markets transactions and incorporated certain provisions specific to healthcare services company IPOs. C&H prepared a comprehensive annotated redline of the initial draft, which identified the Company's positions on key negotiation points and included explanatory annotations for the benefit of Meridian Hale and the underwriters.
On January 25, 2024, Theodore Langston transmitted C&H's markup to Graham Neville at Meridian Hale, accompanied by a cover letter summarizing the key issuer positions and the rationale for each proposed change. Negotiations continued through a series of markup exchanges and telephone conferences between C&H (Langston, Johannsen) and Meridian Hale (Neville, Brennan) over the period from January 25 through February 7, 2024. All material open points were resolved prior to the pricing call on February 8, 2024, and the Underwriting Agreement was executed on the same date.
B. Key Negotiated Terms
Purchase Price. The purchase price per share payable by the underwriters to the Company was $18.80 per share, reflecting the public offering price of $20.00 per share less the underwriting discount of $1.20 per share (6.0%). This purchase price was applied to both the base offering shares and the overallotment shares.
Representations and Warranties. The Underwriting Agreement contained customary representations and warranties by the Company, including representations regarding the accuracy and completeness of the Registration Statement and Prospectus, the Company's corporate existence and good standing, compliance with laws, financial statements, intellectual property, and absence of material adverse changes. C&H successfully negotiated the inclusion of materiality qualifiers and "Material Adverse Effect" (MAE) qualifiers on several representations, thereby limiting the scope of the Company's exposure under these provisions. In particular, C&H narrowed the scope of certain intellectual property representations and litigation representations so that they were qualified to matters material to the Company and its subsidiaries taken as a whole. These changes were consistent with market practice for healthcare SaaS IPOs and were accepted by Meridian Hale after discussion.
Indemnification. The Underwriting Agreement contained standard indemnification provisions. The Company agreed to indemnify the underwriters against losses arising from material misstatements or omissions in the Registration Statement, the Prospectus, or any preliminary prospectus, other than information furnished in writing by the underwriters specifically for inclusion therein (the "underwriter-specific information" carve-out). The underwriters' indemnification of the Company was limited to losses arising from misstatements or omissions in the Registration Statement or Prospectus attributable to information furnished in writing by the underwriters specifically for inclusion therein — a standard limitation consistent with Section 11(b) principles. Contribution provisions were included in the event that indemnification was determined to be unavailable or insufficient. C&H secured a cap on the underwriters' aggregate contribution liability, which was an important negotiation point.
Conditions Precedent to Closing. The Underwriting Agreement included customary conditions precedent to the underwriters' obligation to purchase the shares at closing, including: (i) the continued effectiveness of the Registration Statement; (ii) delivery of the bring-down comfort letter from Kellerman & Associates; (iii) delivery of legal opinions from C&H (issuer's counsel) and Meridian Hale (underwriters' counsel); (iv) delivery of an officers' certificate by Dr. Nathaniel Rourke and David Halderman; (v) delivery of a secretary's certificate by Rachel Moynihan; (vi) good standing certificates from the Delaware Secretary of State and the Massachusetts Secretary of the Commonwealth; (vii) delivery of fully executed lock-up agreements from all required signatories; (viii) receipt of the FINRA no-objections letter; (ix) receipt of NYSE listing approval for the shares; (x) delivery of a DTC eligibility letter from Continental Share Services; and (xi) such other customary conditions as set forth in the agreement.
Lock-Up Provisions. The Underwriting Agreement incorporated a 180-day lock-up from the date of the final prospectus (February 8, 2024), consistent with the standalone lock-up agreements described in Section VII below. Early release from the lock-up required the prior written consent of Whitfield Barrow as Representative. The lock-up provisions included compliance with FINRA Rule 5131 regarding research publication blackout periods in connection with any early release. C&H negotiated specific exception carve-outs, as detailed in Section VII.B below.
Termination Rights. The Underwriting Agreement contained a market-out clause permitting the underwriters to terminate their obligations prior to closing upon the occurrence of certain specified adverse market events, including (without limitation) material adverse changes in financial markets, suspension of trading on the NYSE, and the outbreak of hostilities. A force majeure provision was also included. Whitfield Barrow's initial draft contained a broader list of triggering events than C&H considered appropriate; through negotiation, C&H secured a narrower definition of the triggering events, removing certain provisions that could have permitted termination based on relatively minor market disruptions.
MNPI Representations. The Underwriting Agreement contained representations by the Company regarding material non-public information and compliance with Regulation FD, confirming that the Company had not selectively disclosed material non-public information to the underwriters or any other parties in violation of Regulation FD during the marketing process.
Governing Law. The Underwriting Agreement is governed by the laws of the State of New York.
C. Observations for Future Deals
Several observations from the Underwriting Agreement negotiation are relevant for future healthcare SaaS IPO engagements:
1. Whitfield Barrow's initial draft Underwriting Agreement contained an indemnification scope that was broader than prevailing market practice, particularly with respect to the Company's indemnification of the underwriters. Early identification of this issue and principled pushback by C&H were effective in achieving appropriate market-standard terms. The firm should maintain awareness of evolving underwriter drafting practices and continue to benchmark against recent precedent.
2. The firm should maintain and regularly update its precedent database of underwriting agreement markups for healthcare SaaS IPOs. This database served as an invaluable resource during the AHT negotiation and should be expanded to include the AHT terms.
3. The scope of the market-out clause continues to evolve in response to macro-economic conditions and geopolitical developments. The firm should track market developments in this area, as underwriters may seek to expand termination trigger events in periods of elevated market volatility.
VII. Lock-Up Structure
A. Terms
The lock-up structure for the AHT IPO consisted of standalone lock-up agreements executed in favor of Whitfield Barrow & Co., LLC, as Representative of the several underwriters. The lock-up period was 180 days from the date of the final prospectus, February 8, 2024, resulting in a lock-up expiration date of August 6, 2024.
Approximately 45 signatories executed lock-up agreements. The signatory group included all members of the Board of Directors (Dr. Nathaniel Rourke, Margaret Tsujimoto, Leonard Corbett, Diana Coltrane, Howard Feng, Carolyn Whittemore, and Dr. Samuel Obadina), all executive officers (David Halderman, Rachel Moynihan, and Dr. Priya Subramanian), and all holders of one percent or more of the Company's pre-IPO outstanding common stock. In aggregate, approximately 80,000,000 pre-IPO shares — representing 100% of the pre-IPO shares outstanding — were subject to the lock-up.
B. Exceptions Negotiated by C&H
C&H negotiated the inclusion of specific exception carve-outs to the lock-up restrictions, permitting certain limited transfers and dispositions that are consistent with market practice and the legitimate needs of the Company's insiders:
1. Estate Planning Transfers. Transfers to immediate family members, trusts for the benefit of immediate family members, and other transfers for estate planning purposes, provided that the donees or transferees execute a lock-up agreement substantially identical in form to the original lock-up agreement.
2. Pre-Existing Rule 10b5-1 Plans. Sales pursuant to pre-existing trading plans established in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, to the extent such plans were disclosed in the Registration Statement. A side letter was obtained from Whitfield Barrow confirming the specific parameters for existing plans maintained by Dr. Nathaniel Rourke and Margaret Tsujimoto, including the maximum number of shares subject to each plan and the pricing parameters.
3. Open Market Acquisitions. The lock-up did not apply to shares of common stock acquired by the signatories in the open market after the IPO.
4. RSU Tax Withholding. Signatories were permitted to sell or surrender up to 10% of their locked-up shares in connection with tax withholding obligations arising from the vesting of restricted stock units during the lock-up period.
C. Execution and Tracking
Lock-up execution was tracked by Claire Dempsey using a spreadsheet-based tracker that identified each required signatory, tracked the delivery and execution status of each lock-up agreement, and flagged any outstanding items. All 45 lock-up agreements were fully executed and in the possession of C&H and the Representative prior to the pricing of the offering on February 8, 2024.
In addition, C&H prepared a Lock-Up Release Procedures Letter, transmitted by Theodore Langston to Rachel Moynihan, which outlined the procedures applicable to any potential early release request during the lock-up period. The letter addressed: (i) the requirement for prior written consent of Whitfield Barrow as Representative; (ii) notice period requirements; (iii) FINRA Rule 5131 compliance obligations, including the blackout periods applicable to research publications in connection with any early release announcement; and (iv) recommended board-level approval procedures for any early release request.
D. Market Comparison
The 180-day lock-up period is consistent with market standard practice for healthcare services and SaaS IPOs. While certain recent IPOs in other sectors (particularly technology and consumer) have adopted 90-day lock-up structures or tiered release schedules, the 180-day period remains the norm for healthcare-focused offerings, reflecting the preferences of institutional healthcare investors and the underwriting community.
C&H prepared an internal memorandum (Claire Dempsey) comparing the AHT lock-up terms against eight comparable recent IPO precedents in the healthcare SaaS and healthcare services sectors. The analysis confirmed that AHT's structure — including the 180-day period, the signatory group, and the negotiated exceptions — was consistent with prevailing market practice. The RSU tax withholding exception (permitting sales of up to 10% of locked-up shares) was present in six of the eight precedent transactions, confirming its increasingly standard status. This exception was successfully negotiated into the AHT lock-up over initial resistance from Meridian Hale.
VIII. Overallotment Option
The Underwriting Agreement granted the underwriters an option to purchase up to 3,000,000 additional shares of common stock (representing 15% of the base offering of 20,000,000 shares) at the public offering price of $20.00 per share, less the underwriting discount of $1.20 per share, for a net purchase price of $18.80 per share. The option was exercisable for 30 days following the date of the final prospectus.
The overallotment option was exercised in full on February 27, 2024, by Whitfield Barrow & Co., LLC, acting as the Representative of the several underwriters. The full exercise reflected strong aftermarket trading performance and positive investor reception of the offering, which reduced the need for the underwriters to maintain a stabilization short position.
Settlement of the overallotment shares occurred on March 1, 2024. The Company delivered 3,000,000 shares of common stock against payment of $56,400,000 (3,000,000 shares × $18.80 net per share) through DTC book-entry delivery.
Board resolutions authorizing the issuance of the overallotment shares were adopted on February 27, 2024, concurrent with the exercise of the option. Kellerman & Associates provided a bring-down comfort letter dated March 1, 2024, confirming the continued accuracy of the financial information in the prospectus as of the overallotment settlement date.
The full exercise of the overallotment option brought total shares issued in the offering to 23,000,000 (20,000,000 base plus 3,000,000 overallotment), total gross proceeds to $460,000,000, total underwriting discount to $27,600,000, and total net proceeds to the Company (after underwriting discount) to $432,400,000.
IX. Corporate Governance and Charter Documents
Amended and Restated Certificate of Incorporation. The Company's Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on February 13, 2024, concurrent with the closing of the base offering. The A&R Certificate authorizes 400,000,000 shares of common stock, par value $0.001 per share, and 50,000,000 shares of preferred stock, par value $0.001 per share (blank check preferred, with terms to be fixed by the Board of Directors upon issuance). The Company's capital structure consists of a single class of common stock — no dual-class or multi-class structure was adopted, which was a positive factor in the institutional investor reception of the offering.
Anti-Takeover Provisions. The A&R Certificate and Amended and Restated Bylaws include the following anti-takeover protections, all of which were disclosed in the Registration Statement:
• Prohibition on Stockholder Action by Written Consent. The A&R Certificate provides that any action required or permitted to be taken by stockholders must be taken at a duly called annual or special meeting and may not be taken by written consent.
• Supermajority Vote to Amend Bylaws. The A&R Certificate requires the affirmative vote of the holders of at least 66⅔% of the outstanding voting stock to amend the Company's Amended and Restated Bylaws.
• Advance Notice Bylaw. The A&R Bylaws include advance notice provisions requiring that stockholders provide notice of proposals and director nominations within a window of 90 to 120 days prior to the anniversary of the prior year's annual meeting.
• Blank Check Preferred Stock. The authorization of 50,000,000 shares of blank check preferred stock provides the Board with flexibility to issue preferred stock with rights, preferences, and privileges as determined by the Board, without stockholder approval, which could be used as a defensive mechanism.
• Section 203 of the DGCL. The Company did not opt out of Section 203 of the Delaware General Corporation Law, which imposes restrictions on business combinations with interested stockholders for a period of three years following the date on which such stockholder becomes an interested stockholder.
• Exclusive Forum Provision. The A&R Certificate provides that the Court of Chancery of the State of Delaware is the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of fiduciary duty, (iii) any action arising pursuant to the DGCL, and (iv) any action asserting a claim governed by the internal affairs doctrine.
Amended and Restated Bylaws. The A&R Bylaws were adopted by the Board of Directors on February 8, 2024, and became effective upon closing on February 13, 2024. Key provisions include:
• Classified Board. The Board of Directors is divided into three classes (Class I, Class II, and Class III), with directors in each class serving staggered three-year terms. This classified board structure provides continuity of leadership and serves as an anti-takeover mechanism.
• Proxy Access. The A&R Bylaws include proxy access provisions permitting a stockholder (or group of up to 20 stockholders) owning at least 3% of the Company's outstanding shares continuously for at least three years to nominate a number of director candidates equal to the greater of two directors or 20% of the Board.
• Indemnification and Advancement. The A&R Bylaws provide for indemnification and advancement of expenses for directors and officers to the fullest extent permitted by the DGCL.
Board Committees (Post-IPO). The Board established the following standing committees, each composed entirely of independent directors as required by the NYSE Listed Company Manual:
• Audit Committee: Carolyn Whittemore (Chair), Dr. Samuel Obadina, and Howard Feng. Ms. Whittemore was designated as the Audit Committee financial expert.
• Compensation Committee: Dr. Samuel Obadina (Chair), Diana Coltrane, and Carolyn Whittemore.
• Nominating and Corporate Governance Committee: Leonard Corbett (Chair), Howard Feng, and Dr. Samuel Obadina.
Governance Documents. The following governance documents were adopted effective upon the IPO, and each is available on the Company's investor relations website: committee charters for the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee; Corporate Governance Guidelines; and Code of Business Conduct and Ethics applicable to all directors, officers, and employees. All governance documents were reviewed and confirmed to be compliant with Section 303A of the NYSE Listed Company Manual.
X. Equity Compensation Plans
2014 Stock Incentive Plan. The Company's 2014 Stock Incentive Plan (the "2014 Plan") was adopted at the time of the Company's founding and authorized the issuance of up to 12,000,000 shares of common stock. As of the IPO, 11,200,000 shares had been granted under the 2014 Plan in the form of stock options, of which 8,400,000 were vested. The weighted average exercise price of outstanding options was $3.25 per share. No new awards will be granted under the 2014 Plan following the effectiveness of the 2024 Equity Incentive Plan; however, outstanding awards under the 2014 Plan will continue to be governed by the terms of the 2014 Plan until exercised, expired, or otherwise terminated. The significant differential between the weighted average exercise price ($3.25) and the IPO price ($20.00) was the subject of the "cheap stock" analysis addressed in the SEC Round 2 comments, as discussed in Section IV.C above.
2024 Equity Incentive Plan. The 2024 Equity Incentive Plan (the "2024 Plan") was adopted by the Board of Directors on January 15, 2024, and became effective upon the IPO. The 2024 Plan reserves 10,300,000 shares of common stock for issuance, representing approximately 10% of the Company's post-IPO outstanding shares (103,000,000 shares). The 2024 Plan includes an annual evergreen provision under which the share reserve will automatically increase on January 1 of each calendar year by 3% of the total number of shares of common stock outstanding on December 31 of the preceding year. The 2024 Plan authorizes the grant of incentive stock options (ISOs), non-qualified stock options (NQSOs), restricted stock units (RSUs), stock appreciation rights (SARs), and performance-based awards. Administration of the 2024 Plan is by the Compensation Committee.
2024 Employee Stock Purchase Plan. The 2024 Employee Stock Purchase Plan (the "2024 ESPP") was adopted by the Board of Directors on January 15, 2024, and became effective upon the IPO. The 2024 ESPP reserves 2,060,000 shares of common stock for issuance, representing approximately 2% of the Company's post-IPO outstanding shares. The 2024 ESPP provides eligible employees with the opportunity to purchase shares of common stock at a 15% discount to the lower of the fair market value on the first or last trading day of each semi-annual offering period. The 2024 ESPP is intended to qualify as an "employee stock purchase plan" under Section 423 of the Internal Revenue Code.
Section 83(b) Elections. A total of 14 current employees received restricted stock grants under the 2014 Plan during the period from 2021 to 2022. Each of these employees was eligible to file an election under Section 83(b) of the Internal Revenue Code to include the value of the restricted stock in income at the time of grant rather than at the time of vesting. Sylvia Hartwell confirmed that the compliance status of all 14 Section 83(b) elections has been verified, and all elections were timely filed with the Internal Revenue Service within 30 days of the applicable grant date.
XI. Stockholder Agreements — Termination and Survival
Amended and Restated Investors' Rights Agreement. The Amended and Restated Investors' Rights Agreement, dated October 22, 2020, among the Company, Brindoval Trelvon Partners Fund IV, L.P., Ridgeline Growth Equity Fund III, LLC, and the founders, terminated by its terms upon the consummation of a "Qualified IPO," defined as an initial public offering generating gross proceeds in excess of $200,000,000 on a national securities exchange. The AHT IPO, with base gross proceeds of $400,000,000 on the New York Stock Exchange, satisfied the Qualified IPO threshold. A termination agreement was executed by the Company, Brindoval Trelvon Partners Fund IV, L.P., Ridgeline Growth Equity Fund III, LLC, Dr. Nathaniel Rourke, and Margaret Tsujimoto, confirming the termination of the Investors' Rights Agreement and the release of all rights and obligations thereunder, except that registration rights were preserved under the separate Registration Rights Agreement described below.
Amended and Restated Voting Agreement. The Amended and Restated Voting Agreement among the Company, the institutional investors, and the founders terminated upon the IPO by its terms. A termination agreement was executed by all parties confirming the termination.
Amended and Restated Registration Rights Agreement. The Amended and Restated Registration Rights Agreement became effective upon the IPO and survives the closing. This agreement grants Brindoval Trelvon Partners Fund IV, L.P. and Ridgeline Growth Equity Fund III, LLC: (i) two demand registration rights, exercisable by either investor at any time following the expiration of the lock-up period; (ii) piggyback registration rights on any registered offering by the Company; and (iii) the right to request that the Company file a shelf registration statement on Form S-3 after the Company becomes eligible for such filing (i.e., 12 months post-IPO). The agreement includes a 180-day standstill provision coterminous with the lock-up period.
XII. Credit Facility Amendment and Payoff
Keypoint Credit Facility. The Company maintains a $150,000,000 senior secured revolving credit facility entered into on March 15, 2022. The administrative agent is Keypoint National Bank, N.A. (200 Public Square, Cleveland, Ohio 44114), and Stonemill Capital Bank (140 Broadway, New York, New York 10005) participates as a syndicate member. The credit facility matures on March 15, 2027. Borrowings bear interest at a rate equal to Term SOFR plus 200 basis points. The credit facility contains the following financial covenants: (i) a Total Net Leverage Ratio not to exceed 3.50x; and (ii) a Fixed Charge Coverage Ratio of not less than 1.25x.
First Amendment to Credit Agreement. The First Amendment to the Credit Agreement was executed on January 18, 2024. The amendment was prepared and negotiated by C&H and addressed the following IPO-related modifications: (i) the definition of "Change of Control" was amended to exclude the IPO and any related changes in the Company's ownership structure; (ii) a "Permitted Equity Issuance" carve-out was added to permit the Company to issue equity securities in the IPO without triggering mandatory prepayment or other restrictive provisions; and (iii) the mandatory prepayment provisions were updated to address the application of IPO proceeds, specifically providing that the credit facility repayment from IPO proceeds would constitute a voluntary prepayment not subject to any prepayment premium.
Payoff. The outstanding drawn balance on the revolving credit facility of approximately $65,000,000 was repaid from IPO proceeds at the closing on February 13, 2024. In advance of closing, Keypoint National Bank issued a payoff letter confirming: (i) the outstanding principal balance and accrued interest as of the anticipated payoff date; (ii) the per diem interest amount; (iii) wire transfer instructions for payment; and (iv) the lien release mechanics, including the filing of UCC-3 termination statements and release of security interests upon receipt of payoff funds.
C&H Internal Memo. Eric Johannsen prepared an internal memorandum summarizing the key changes effected by the First Amendment to the Credit Agreement and analyzing the impact on the Company's financial covenants and events of default, including the effect of the IPO proceeds and the revolving credit facility payoff on the Total Net Leverage Ratio and Fixed Charge Coverage Ratio calculations.
Tax Treatment. Sylvia Hartwell analyzed the tax treatment of the approximately $65,000,000 credit facility repayment, including the deductibility of previously accrued interest (at the SOFR plus 200 basis points rate) and the lien release implications.
XIII. D&O Insurance Program
In connection with the IPO, the Company procured a directors and officers liability insurance program with a total tower of $100,000,000 in coverage. The program is structured in three layers:
Primary Layer. Northbridge Specialty Insurance Company provides $50,000,000 per occurrence and in the aggregate, on a claims-made basis, with Side A (non-indemnifiable loss), Side B (corporate reimbursement), and Side C (entity securities claims) coverage. The policy number is NSI-IPO-2024-00473. The annual premium is $1,875,000. The effective date is February 8, 2024, coterminous with the effectiveness of the Registration Statement and pricing of the offering.
First Excess Layer. Pinnacle Re Assurance Ltd. (domiciled in Bermuda) provides $25,000,000 in excess of $50,000,000. This policy follows form to the primary policy and attaches upon exhaustion of the Northbridge primary layer.
Second Excess Layer. Atlas Guard Insurance Company (domiciled in Illinois) provides $25,000,000 in excess of $75,000,000. This policy follows form to the primary policy and attaches upon exhaustion of the Pinnacle Re first excess layer.
C&H Review. C&H reviewed the terms of all three policies and identified the following key provisions for management attention: (i) IPO-specific exclusions applicable to claims arising from the offering process; (ii) a prior acts exclusion establishing a retroactive date; (iii) a regulatory proceeding exclusion; (iv) notice requirements (including the obligation to provide prompt written notice of claims and circumstances that may give rise to claims); and (v) subrogation waivers. C&H recommended certain endorsements to the primary policy to Rachel Moynihan, including endorsements to narrow the scope of the IPO exclus